EMMAUS LIFE SCIENCES INC - EMMA STOCK NEWS

Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported a 19% increase in shipment volume for the three months ended March 31, 2023, delivering 8,248 boxes of Endari^® compared to 6,930 boxes in Q4 2022. This trend indicates significant growth in the treatment of sickle cell disease. The company is set to release complete interim financial results in its upcoming Form 10-Q filing. Endari^®, a prescription-grade L-glutamine oral powder, is approved for treating sickle cell disease and is marketed in several countries. The CEO emphasizes the positive trajectory of shipments while noting that full financial data will follow soon.

Emmaus Life Sciences (OTCQX: EMMA) reported its 2022 financial results, with net revenues of $18.4 million, down from $20.6 million in 2021. The decline was primarily due to increased distributor discounts, despite higher sales volume of Endari. Operating expenses decreased to $22.4 million, leading to a loss from operations of $6.6 million, slightly worse than the previous year's loss of $6.1 million. However, other expenses dropped to $4.0 million, resulting in a reduced net loss of $10.6 million compared to $15.9 million in 2021. Liquidity remains a concern with cash reserves of only $2.0 million.

Emmaus Life Sciences (OTCQX: EMMA) announced a meeting between Dr. Yutaka Niihara, CEO, and Bhagat Singh Koshyari, Governor of Maharashtra, on December 16, 2022, in Mumbai. The discussion focused on the needs of over 20 million individuals suffering from sickle cell disease (SCD) in India and the potential benefits of Endari®, a treatment approved in the U.S. and select regions for patients aged five and older. While Endari is accessible in some areas, it is not yet available in India.

Emmaus Life Sciences (OTCQX: EMMA) celebrated Dr. Yutaka Niihara's recognition by India's Minister of State, Arun Halder, for his work on Endari® at an event in Mumbai on December 16, 2022. Sickle cell disease (SCD) affects over 20 million people in India, particularly among tribal communities. Endari® is approved in the U.S. and other regions but not yet in India. Emmaus aims to explore market entry opportunities in India to provide treatments for SCD patients. Forward-looking statements regarding market access are included in the PR.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) has secured marketing authorization for its sickle cell disease treatment, Endari®, from the Kuwaiti Ministry of Health. This approval marks Kuwait as the third Gulf Cooperation Council (GCC) country to endorse Endari®, following similar approvals in the United Arab Emirates and Qatar earlier in the year. Dr. Yutaka Niihara stated that this progress is crucial for expanding Endari's availability to sickle cell patients in the region, with expectations of positive operating cash flows in 2023.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported a 15% increase in net revenue to $4.9 million for Q3 2022, despite a decrease compared to $5.8 million in Q3 2021. The company faced challenges with production delays but remains optimistic for Q4 sales. Loss from operations decreased to $0.7 million from $1.4 million in Q2 2022. However, total operating expenses fell to $5.1 million from $5.4 million year-over-year, and liquidity issues persist with cash reserves at $1.2 million. Emmaus continues to explore refinancing options to address current liabilities.

Emmaus Life Sciences (OTCQX: EMMA) announced a partnership with Kier (Junior) Spates from the Steve Harvey Morning Show to raise awareness about sickle cell disease (SCD) and promote Endari, its L-glutamine oral powder treatment. This collaboration aims to destigmatize SCD and inform millions of listeners about available treatment options as many SCD patients hesitate to seek help. Endari has been FDA-approved since July 2017 and is indicated for adults and children over five, yet faced challenges in reaching underrepresented communities. The initiative seeks to address healthcare access disparities.